Cargando…

Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study

BACKGROUND: Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss and improve metabolic factors, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarathurai, Preman, Sajadieh, Ahmad, Anholm, Christian, Kristiansen, Ole P., Haugaard, Steen B., Nielsen, Olav W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791686/
https://www.ncbi.nlm.nih.gov/pubmed/33413428
http://dx.doi.org/10.1186/s12933-020-01205-2
_version_ 1783633645383188480
author Kumarathurai, Preman
Sajadieh, Ahmad
Anholm, Christian
Kristiansen, Ole P.
Haugaard, Steen B.
Nielsen, Olav W.
author_facet Kumarathurai, Preman
Sajadieh, Ahmad
Anholm, Christian
Kristiansen, Ole P.
Haugaard, Steen B.
Nielsen, Olav W.
author_sort Kumarathurai, Preman
collection PubMed
description BACKGROUND: Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss and improve metabolic factors, thus modulating factors associated with diastolic dysfunction. We have previously reported the effects of liraglutide on systolic function, and in this current study we explore the effects of liraglutide on diastolic function parameters in patients with stable CAD, preserved left ventricular ejection fraction (LVEF), and newly diagnosed T2DM. METHODS: Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study. 2D-echocardiography using tissue velocity imaging was used for assessment of diastolic function parameters. Early diastolic filling velocity (E), late atrial filling velocity (A), E-wave deceleration time (EDT) and E/A ratio was assessed from the pulse wave (PW)-Doppler velocity recording of the mitral inflow. Peak early diastolic annular velocities (e′) was measured from color tissue doppler images. RESULTS: Liraglutide, when compared to placebo, induced a significant reduction in average e′ and lateral e′ velocities (– 0.57 cm/s [– 1.05 to − 0.08] and –0.74 cm/s [–1.32 to –0.15], respectively). Adjusted for the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54], the changes were not significant. No significant changes in other diastolic function parameters were observed. CONCLUSIONS: Liraglutide therapy did not improve any diastolic function parameters in subjects with T2DM, CAD, and preserved LVEF. Instead, a deterioration in e’ was observed, which was associated to an increase in heart rate induced by liraglutide therapy. Trial registration Clinical Trial Registration: http://www.clinicaltrials.gov (unique identifier: NCT01595789) (first submitted May 8, 2012)
format Online
Article
Text
id pubmed-7791686
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77916862021-01-11 Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study Kumarathurai, Preman Sajadieh, Ahmad Anholm, Christian Kristiansen, Ole P. Haugaard, Steen B. Nielsen, Olav W. Cardiovasc Diabetol Original Investigation BACKGROUND: Diastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss and improve metabolic factors, thus modulating factors associated with diastolic dysfunction. We have previously reported the effects of liraglutide on systolic function, and in this current study we explore the effects of liraglutide on diastolic function parameters in patients with stable CAD, preserved left ventricular ejection fraction (LVEF), and newly diagnosed T2DM. METHODS: Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study. 2D-echocardiography using tissue velocity imaging was used for assessment of diastolic function parameters. Early diastolic filling velocity (E), late atrial filling velocity (A), E-wave deceleration time (EDT) and E/A ratio was assessed from the pulse wave (PW)-Doppler velocity recording of the mitral inflow. Peak early diastolic annular velocities (e′) was measured from color tissue doppler images. RESULTS: Liraglutide, when compared to placebo, induced a significant reduction in average e′ and lateral e′ velocities (– 0.57 cm/s [– 1.05 to − 0.08] and –0.74 cm/s [–1.32 to –0.15], respectively). Adjusted for the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54], the changes were not significant. No significant changes in other diastolic function parameters were observed. CONCLUSIONS: Liraglutide therapy did not improve any diastolic function parameters in subjects with T2DM, CAD, and preserved LVEF. Instead, a deterioration in e’ was observed, which was associated to an increase in heart rate induced by liraglutide therapy. Trial registration Clinical Trial Registration: http://www.clinicaltrials.gov (unique identifier: NCT01595789) (first submitted May 8, 2012) BioMed Central 2021-01-07 /pmc/articles/PMC7791686/ /pubmed/33413428 http://dx.doi.org/10.1186/s12933-020-01205-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Kumarathurai, Preman
Sajadieh, Ahmad
Anholm, Christian
Kristiansen, Ole P.
Haugaard, Steen B.
Nielsen, Olav W.
Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title_full Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title_fullStr Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title_full_unstemmed Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title_short Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
title_sort effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791686/
https://www.ncbi.nlm.nih.gov/pubmed/33413428
http://dx.doi.org/10.1186/s12933-020-01205-2
work_keys_str_mv AT kumarathuraipreman effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy
AT sajadiehahmad effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy
AT anholmchristian effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy
AT kristiansenolep effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy
AT haugaardsteenb effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy
AT nielsenolavw effectsofliraglutideondiastolicfunctionparametersinpatientswithtype2diabetesandcoronaryarterydiseasearandomizedcrossoverstudy